PharmaCielo Ltd.

PCLO

CA71716K1012

Pharmaceuticals

Market Closed - Toronto S.E. Other stock markets 03:58:13 2024-04-26 pm EDT			5-day change	1st Jan Change
0.15 ^CAD	-3.23%		-9.09%	-16.67%

Apr. 10	PharmaCielo Ltd. announced that it expects to receive CAD 2 million in funding	CI
Jan. 04	Benuvia and PharmaCielo Announce Strategic Partnership to Manufacture cGMP Pharmaceutical-Grade CBD Isolate and Related Products	CI

Pharmacielo Ltd. Announces Earnings Results for the First Quarter Ended March 31, 2021

May 31, 2021 at 07:45 am EDT

PharmaCielo Ltd. announced earnings results for the first quarter ended March 31, 2021. For the quarter, the company generated total revenue of CAD 675,264 compared to CAD 514,409 a year ago. Net loss was CAD 6,542,056 compared to CAD 6,317,998 a year ago. Basic & diluted net loss per common was CAD 0.05 against CAD 0.06 a year ago.

Latest news about PharmaCielo Ltd.

PharmaCielo Ltd. announced that it expects to receive CAD 2 million in funding	Apr. 09	CI
Benuvia and PharmaCielo Announce Strategic Partnership to Manufacture cGMP Pharmaceutical-Grade CBD Isolate and Related Products	Jan. 04	CI
PharmaCielo Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 29	CI
PharmaCielo Raises $3.3 Million Under Non-Brokered Private Placement	23-10-06	MT
PharmaCielo Ltd. announced that it has received CAD 4.78 million in funding	23-10-05	CI
PharmaCielo Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-29	CI
Pharmacielo Ltd. Appoints Marc Lustig as CEO	23-07-11	CI
Pharmacielo Ltd. Announces Board Changes	23-07-11	CI
PharmaCielo Ltd. announced that it expects to receive CAD 5 million in funding	23-06-28	CI
PharmaCielo Ltd. announced that it has received CAD 12.825 million in funding	23-06-28	CI
PharmaCielo Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-29	CI
PharmaCielo Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-05-01	CI
PharmaCielo Ltd. Auditor Raises 'Going Concern' Doubt	23-04-30	CI
PharmaCielo Reports Purchase Order for API from Brazilian Pharmaceutical Firm	23-02-08	MT
Pharmacielo Ltd. Receives Purchase Order for API from Brazilian Pharmaceutical Company	23-02-08	CI
PharmaCielo Receives First Commercial Purchase Order from Ease Labs Pharma in Brazil	23-01-30	MT
PharmaCielo Receives First Commercial Purchase Order from Ease Labs Pharma	23-01-30	CI
PharmaCielo Ltd.(TSXV:PCLO) dropped from S&P/TSX Venture Composite Index	23-01-23	CI
Pharmacielo Reports First Shipment of Pharmaceutical Grade Cannabis Extract to Customer in Morocco	22-12-05	MT
Pharmacielo Announces First Shipment of Pharmaceutical Grade Cannabis Extract to Customer in Morocco	22-12-05	CI
Pharmacielo Extends the Maturity of 9.1-Million Warrants by Two Years	22-11-22	MT
PharmaCielo Narrows Q3 Loss, Revenue Drops	22-10-31	MT
Earnings Flash (PCLOF) PHARMACIELO Reports Q3 Revenue C$475,000	22-10-31	MT
PharmaCielo Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-10-28	CI
PharmaCielo Reports Second Shipment of Pharmaceutical-Grade Cannabis Extract to Customer in Uruguay; Up 5%	22-10-12	MT

Chart PharmaCielo Ltd.

Duration

Period

More charts

Company Profile

PharmaCielo Ltd. is a Canada-based company with a focus on ethical and sustainable processing and supplying of all natural, pharmaceutical-grade medical cannabis products to channel distributors. The Company has two subsidiaries, PharmaCielo Colombia Holdings S.A.S. (PharmaCielo Colombia) and Ubiquo Telemedicina S.A.S. (Ubiquo). PharmaCielo Colombia cultivates and processes the Companyâs all-natural cannabis into standardized, medicinal-grade oil extracts and related products. In Colombia, PharmaCielo Colombia is a licensed cultivator, producer, and distributor of both TetraHydroCannabinol (THC) and Cannabidiol (CBD) medical cannabis for use in Colombia, international export, and research purposes. Ubiquo is a knowledge management and medical consultation system that focuses on creating access to healthcare for Colombians. Ubiquo is a technology platform and a user interface that allows doctors and patients to communicate. Ubiquo is used as a communication tool.

Sector

Pharmaceuticals

Calendar

2024-04-28 - Q4 2023 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Alternative Medicine

	1st Jan change	Capi.
PHARMACIELO LTD.	-16.67%	19.21M
SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD.	-15.13%	4.49B
TASLY PHARMACEUTICAL GROUP CO., LTD	-9.75%	3.06B
TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED	+2.14%	3.04B
SHANDONG BUCHANG PHARMACEUTICALS CO., LTD.	-6.82%	2.61B
HENAN LINGRUI PHARMACEUTICAL CO., LTD.	+47.87%	1.81B
TIBET CHEEZHENG TIBETAN MEDICINE CO., LTD.	+0.09%	1.66B
GUANGYUYUAN CHINESE HERBAL MEDICINE CO., LTD.	-7.89%	1.63B
TIANJIN CHASE SUN PHARMACEUTICAL CO.,LTD	-12.97%	1.55B
ZHEJIANG JOLLY PHARMACEUTICAL CO.,LTD	+33.40%	1.41B